SCHEMBL1304353

SCHEMBL1304353

CC(=O)N1C(=O)/C(=C/c2ccc(/C=C3/C(=O)Nc4ccc(C(=O)[O-])cc43)o2)c2ccccc21.[Na+]

nearest known ligand 0.46

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
THRB known ✓ P10828 1/20 0.43
PTPN1 P18031 7/20 0.46
PTPN2 P17706 1/20 0.44
ALDH1A1 P00352 2/20 0.43
DYRK1A Q13627 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
PIM1 P11309 2/20 0.42
TLK2 Q86UE8 5/20 0.42
RET P07949 2/20 0.39
PIM2 Q9P1W9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1304859 0.93 ALDH1A1 (0.43) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL3130088 0.91 PIM1 (0.52) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL3130082 0.91 PIM1 (0.52) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL1304354 0.90 PIM1 (0.52) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL1304351 0.90 PIM1 (0.52) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL1304522 0.86 ALDH1A1 (0.58) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL1304521 0.86 ALDH1A1 (0.58) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL1304433 0.83 PIM1 (0.52) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL1304434 0.83 PIM1 (0.52) PTPN1PTPN2ALDH1A1DYRK1AMEN1
SCHEMBL1304322 0.83 RET (0.52) ALDH1A1DYRK1AMEN1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053461-B2 Oxindole derivative THERAVALUES CORPORATION (JP) 2011-11-08 US disclosed
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE THERAVALUES CORPORATION (JP) 2010-03-25 US disclosed
EP-2130829-A1 NOVEL HYDROXYINDOLE DERIVATIVE Theravalues Corporation (JP) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE CYP2C9, HDAC10, SIGMAR1 THRB 2003/4885PTPN1 2819/4885PTPN2 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.